These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 32383251)

  • 1. The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic.
    Shah M; Sachdeva M; Dodiuk-Gad RP
    Dermatol Ther; 2020 Jul; 33(4):e13524. PubMed ID: 32383251
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulators split on antimalarials for COVID-19.
    Jaffe S
    Lancet; 2020 Apr; 395(10231):1179. PubMed ID: 32278373
    [No Abstract]   [Full Text] [Related]  

  • 3. The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale.
    Schluger NW
    Ann Intern Med; 2020 Oct; 173(8):662-663. PubMed ID: 32673059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.
    Jakhar D; Kaur I
    Nat Med; 2020 May; 26(5):632. PubMed ID: 32269358
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
    Yazdany J; Kim AHJ
    Ann Intern Med; 2020 Jun; 172(11):754-755. PubMed ID: 32232419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.
    Peschken CA
    J Rheumatol; 2020 Jun; 47(6):787-790. PubMed ID: 32269064
    [No Abstract]   [Full Text] [Related]  

  • 7. Cutaneous sıde-effects of the potential COVID-19 drugs.
    Türsen Ü; Türsen B; Lotti T
    Dermatol Ther; 2020 Jul; 33(4):e13476. PubMed ID: 32358890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era.
    Grandolfo M; Romita P; Bonamonte D; Cazzato G; Hansel K; Stingeni L; Conforti C; Giuffrida R; Foti C
    Dermatol Ther; 2020 Jul; 33(4):e13499. PubMed ID: 32362051
    [No Abstract]   [Full Text] [Related]  

  • 9. [Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?].
    Defoort-Dhellemmes S
    J Fr Ophtalmol; 2020 Jun; 43(6):548-549. PubMed ID: 32451138
    [No Abstract]   [Full Text] [Related]  

  • 10. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
    Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
    Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug Evaluation during the Covid-19 Pandemic.
    Rome BN; Avorn J
    N Engl J Med; 2020 Jun; 382(24):2282-2284. PubMed ID: 32289216
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
    Oren O; Yang EH; Gluckman TJ; Michos ED; Blumenthal RS; Gersh BJ
    Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008688. PubMed ID: 32436730
    [No Abstract]   [Full Text] [Related]  

  • 13. A Word of Caution in the Use of Hydroxychloroquine in the Elderly COVID-19 Population.
    Martinez Navarro W; Ly L; Segal MS; Shukla AM
    Asia Pac J Ophthalmol (Phila); 2020; 9(4):374-375. PubMed ID: 32740071
    [No Abstract]   [Full Text] [Related]  

  • 14. Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2.
    Ingraham NE; Boulware D; Sparks MA; Schacker T; Benson B; Sparks JA; Murray T; Connett J; Chipman JG; Charles A; Tignanelli CJ
    Crit Care; 2020 Apr; 24(1):182. PubMed ID: 32345336
    [No Abstract]   [Full Text] [Related]  

  • 15. Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.
    Islam M
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):78. PubMed ID: 32723461
    [No Abstract]   [Full Text] [Related]  

  • 16. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
    Gao J; Hu S
    Biosci Trends; 2020 May; 14(2):156-158. PubMed ID: 32281583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine and COVID-19.
    Sinha N; Balayla G
    Postgrad Med J; 2020 Sep; 96(1139):550-555. PubMed ID: 32295814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
    Avidan MS; Dehbi HM; Delany-Moretlwe S
    N Engl J Med; 2020 Sep; 383(11):1087-1088. PubMed ID: 32668106
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
    Khan MS; Butler J
    N Engl J Med; 2020 Sep; 383(11):1088. PubMed ID: 32668107
    [No Abstract]   [Full Text] [Related]  

  • 20. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
    Tekwani BL
    N Engl J Med; 2020 Sep; 383(11):1088-1089. PubMed ID: 32668108
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.